Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Feifel

Showing results (91-100 of 112) with videos related to

Pageof 12
Sort By:
Aging Brain|March 13, 2023
Chronic oxytocin administration in older men modulates functional connectivity during animacy perceptionPedro A Valdes-Hernandez, Rebecca Polk, Marilyn Horta, et al.
Biological Psychiatry|July 10, 2010
Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patientsDavid Feifel, Kai Macdonald, Angel Nguyen, et al.
The British Journal of Psychiatry : the Journal of Mental Science|January 5, 2011
Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapineMichael D Lesem, Tram K Tran-Johnson, Robert A Riesenberg, et al.
Psychopharmacology|July 13, 2011
Efficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover studyGeorge Apostol, Walid Abi-Saab, Christopher J Kratochvil, et al.
Psychopharmacology|May 13, 2021
Safety and tolerability of chronic intranasal oxytocin in older men: results from a randomized controlled trialJillian M Rung, Marilyn Horta, Erin M Tammi, et al.
Focus (American Psychiatric Publishing)|June 24, 2022
Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled TrialLior Carmi, Aron Tendler, Alexander Bystritsky, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 14, 2023
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medicationGuy M Goodwin, Megan Croal, David Feifel, et al.
The American Journal of Psychiatry|May 22, 2019
Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled TrialLior Carmi, Aron Tendler, Alexander Bystritsky, et al.
Journal of Affective Disorders|November 8, 2023
National Network of Depression Centers position statement: Insurance coverage for intravenous ketamine in treatment-resistant major depressive disorderMark J Niciu, Robert C Meisner, Brent R Carr, et al.
Journal of Psychopharmacology (Oxford, England)|February 5, 2026
Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compoundsBenjamin R Lewis, Matthew J Reid, Andrew M Novick, et al.
Pageof 12

Showing results (91-100 of 112) with videos related to

Sort By:
Pageof 12
Aging Brain|March 13, 2023
Chronic oxytocin administration in older men modulates functional connectivity during animacy perceptionPedro A Valdes-Hernandez, Rebecca Polk, Marilyn Horta, et al.
Biological Psychiatry|July 10, 2010
Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patientsDavid Feifel, Kai Macdonald, Angel Nguyen, et al.
The British Journal of Psychiatry : the Journal of Mental Science|January 5, 2011
Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapineMichael D Lesem, Tram K Tran-Johnson, Robert A Riesenberg, et al.
Psychopharmacology|July 13, 2011
Efficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover studyGeorge Apostol, Walid Abi-Saab, Christopher J Kratochvil, et al.
Psychopharmacology|May 13, 2021
Safety and tolerability of chronic intranasal oxytocin in older men: results from a randomized controlled trialJillian M Rung, Marilyn Horta, Erin M Tammi, et al.
Focus (American Psychiatric Publishing)|June 24, 2022
Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled TrialLior Carmi, Aron Tendler, Alexander Bystritsky, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 14, 2023
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medicationGuy M Goodwin, Megan Croal, David Feifel, et al.
The American Journal of Psychiatry|May 22, 2019
Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled TrialLior Carmi, Aron Tendler, Alexander Bystritsky, et al.
Journal of Affective Disorders|November 8, 2023
National Network of Depression Centers position statement: Insurance coverage for intravenous ketamine in treatment-resistant major depressive disorderMark J Niciu, Robert C Meisner, Brent R Carr, et al.
Journal of Psychopharmacology (Oxford, England)|February 5, 2026
Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compoundsBenjamin R Lewis, Matthew J Reid, Andrew M Novick, et al.
Pageof 12